Last reviewed · How we verify
Continue the antimicrobial treatment
This is a treatment directive to continue an existing antimicrobial regimen rather than a specific drug entity.
This is a treatment directive to continue an existing antimicrobial regimen rather than a specific drug entity. Used for Continuation of antimicrobial treatment for unspecified infection.
At a glance
| Generic name | Continue the antimicrobial treatment |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This entry represents a clinical instruction to maintain ongoing antimicrobial therapy rather than a distinct pharmaceutical agent. The actual mechanism would depend on the specific antimicrobial agent(s) being continued, which is not specified in the provided information.
Approved indications
- Continuation of antimicrobial treatment for unspecified infection
Common side effects
Key clinical trials
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia (NA)
- The Personalised Antibiotic Duration for Cellulitis (PAD-C) Study
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) (NA)
- Effect of Intrarectal Ice Application on Pain, Anxiety, Cortisol Levels, Development of Complications, and Hospital Readmission in Transrectal Ultrasound-Guided Prostate Biopsy (NA)
- Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: